In this opinion article, the authors discuss multicentre clinical trials in Asia. Asians have been under-represented in many clinical trials; differences in cardiovascular disease risk and drug responses between Asians and white people underscore the importance of ethnicity-specific intervention testing. Challenges specific to Asia need to be addressed before Asia can rival Europe and the USA as a location-of-choice for clinical trials.
- Joey S. W. Kwong
- Cheuk-Man Yu
